FLT3 and acute myeloid leukemia: To further improve the response in R/R FLT3-mutated AML, the combination of VEN and gilteritinib was recently studied in 56 patients, of which 75% achieved a composite morphologic remission (including CR/CRi/CRp/MLFS): 15 (60%), 11 (44%) and 5 (20%) of 25 evaluable achieved an NGS-MRD < 1%, <0.1%, and 0.01%, respectively.